强化收缩压降低对合并心血管危险因素的2型糖尿病成人终末期肾病及肾功能下降的影响:ACCORD-BP与SPRINT的事后分析
该事后分析纳入1966例符合SPRINT入选标准的ACCORD-BP标准降糖组参与者,比较强化(<120 mmHg)与标准(<140 mmHg)收缩压降低对肾脏复合结局的影响;强化组与标准组肾脏复合结局发生率分别为9.5与7.2例/1000人年(HR 1.35,95%CI 0.85-2.14;P=0.20),强化收缩压降低未增加主要不良肾脏事件风险。
要点
- 强化组与标准组肾脏复合结局发生率分别为9.5与7.2例/1000人年,HR 1.35(95%CI 0.85-2.14;P=0.20)。
- 强化收缩压降低对中度白蛋白尿风险无影响(HR 0.96,95%CI 0.76-1.20)。
- 强化收缩压降低对重度白蛋白尿风险无影响(HR 0.92,95%CI 0.66-1.28)。
核心结论
- 该事后亚组分析提示,在合并心血管危险因素的2型糖尿病患者中,强化收缩压降低不增加主要不良肾脏事件风险。
研究设计与样本
- ACCORD-BP事后亚组分析,纳入标准降糖组中符合SPRINT入选条件的心血管危险因素参与者。
- 采用Cox比例风险回归比较强化(<120 mmHg)与标准(<140 mmHg)收缩压降低组间的肾脏复合结局风险。
主要发现
- 研究队列共1966例符合SPRINT入选标准的ACCORD-BP参与者(40%为女性),平均年龄63岁。
- 随机分组后强化组与标准组平均收缩压分别为120±14与134±15 mmHg。
- 肾脏复合结局在强化组与标准组的发生率分别为9.5与7.2例/1000人年(HR 1.35,95%CI 0.85-2.14;P=0.20)。
- 强化收缩压降低对中度白蛋白尿风险无影响(HR 0.96,95%CI 0.76-1.20)。
- 强化收缩压降低对重度白蛋白尿风险无影响(HR 0.92,95%CI 0.66-1.28)。
关键数值与推荐
- 肾脏复合结局定义为透析、肾移植、持续性估算肾小球滤过率(eGFR)<15 mL/min/1.73 m2、血清肌酐>3.3 mg/dL或持续性eGFR下降≥57%的复合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effects of intensive systolic blood pressure (SBP) lowering on the risk of major adverse kidney outcomes in people with type 2 diabetes mellitus (T2DM) and/or prediabetes and cardiovascular risk factors. RESEARCH DESIGN AND METHODS: This post hoc ACCORD-BP subgroup analysis included participants in the standard glucose-lowering arm with cardiovascular risk factors required for SPRINT eligibility. Cox proportional hazards regression models compared the hazard for the composite of dialysis, kidney transplant, sustained estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2, serum creatinine >3.3 mg/dL, or a sustained eGFR decline ≥57% between the intensive (<120 mmHg) and standard (<140 mmHg) SBP-lowering arms. RESULTS: The study cohort included 1,966 SPRINT-eligible ACCORD-BP participants (40% women) with a mean age of 63 years. The mean SBP achieved after randomization was 120 ± 14 and 134 ± 15 mmHg in the intensive and standard arms, respectively. The kidney composite outcome occurred at a rate of 9.5 and 7.2 events per 1,000 person-years in the intensive and standard BP arms (hazard ratio [HR] 1.35 [95% CI 0.85-2.14]; P = 0.20). Intensive SBP lowering did not affect the risk of moderately (HR 0.96 [95% CI 0.76-1.20]) or severely (HR 0.92 [95% CI 0.66-1.28]) increased albuminuria. Including SPRINT participants with prediabetes in the cohort did not change the overall results. CONCLUSIONS: This post hoc subgroup analysis suggests that intensive SBP lowering does not increase the risk of major adverse kidney events in individuals with T2DM and cardiovascular risk factors.
引用
- Tawfik YMK, Van Tassell BW, Dixon DL, et al. Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT. Diabetes Care. 2023. PMID: 36787937. doi:10.2337/dc22-2040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。